Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Emtricitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 1.00 |
| ▸ | POLG | P54098 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.63 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.63 |
| ▸ | DCK | P27707 | 7/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emtricitabine, (+/-)- SCHEMBL122131 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL3230512 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL12202574 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL6903677 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL5427218 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL6362885 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL3722124 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL39708 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL22413085 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL12662838 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247900-B1 | ZINC PIGMENT FOR WATERBORNE CORROSION COATINGS | SUN CHEMICAL CORP (US) | 2024-06-26 | — | — | EP | claimed |
| US-20230285364-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | SERVIER PHARMACEUTICALS LLC | 2023-09-14 | — | — | US | claimed |
| EP-4171552-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | Les Laboratoires Servier (FR) | 2023-05-03 | — | — | EP | claimed |
| WO-2021262881-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | SERVIER PHARMACEUTICALS, LLC (US) | 2021-12-30 | — | — | WO | claimed |
| EP-3544601-A1 | BENZAMIDE AND ACTIVE COMPOUND COMPOSITIONS AND METHODS OF USE | Translational Drug Development, LLC (US) | 2019-10-02 | — | — | EP | claimed |
| WO-2018098401-A1 | BENZAMIDE AND ACTIVE COMPOUND COMPOSITIONS AND METHODS OF USE | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-31 | — | — | WO | claimed |
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | claimed |
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | claimed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | claimed |
| US-5538975-A | (-)-4-AMINO-5-FLUORO-1-(2-HYDROXYMETHYL-1,3-OXATHIOLAN-5YL) -(1H)-PYRIMIDIN-2-ONE AND DERIVATIVES; ANTIVIRAL AGENT | BIOCHEM PHARMA, INC. (CA) | 1996-07-23 | — | — | US | claimed |
| US-5486520-A | VIRICIDE | BIOCHEMPHARMA, INC. (CA) | 1996-01-23 | — | — | US | claimed |
| WO-1995012400-A1 | NOVEL ENZYME INHIBITORS, THEIR SYNTHESIS, AND METHODS FOR USE | UAB RESEARCH FOUNDATION (US) | 1995-05-11 | — | — | WO | claimed |
| EP-0574487-A1 | USE OF 5-FLUORO-2'-DEOXY-3'-THIACYTIDINE FOR THE TREATMENT OF HEPATITIS B | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-22 | — | — | EP | claimed |
| EP-0574457-A1 | ANTIVIRAL NUCLEOSIDE COMBINATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-22 | — | — | EP | claimed |
| US-5234913-A | Synergistic mixture of 1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocystosine and zidovudine | BURROUGHS WELLCOME CO. (US) | 1993-08-10 | — | — | US | claimed |
| EP-0515144-A1 | 1,3-Oxathiolanes useful in the treatment of hepatitis | BIOCHEM PHARMA INC. (CA) | 1992-11-25 | — | — | EP | claimed |
| WO-1992018517-A1 | METHOD OF TREATING OR PREVENTING HEPATITIS B VIRUS | YALE UNIVERSITY (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1992015309-A1 | ANTIVIRAL NUCLEOSIDE COMBINATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | claimed |
| WO-1992015308-A1 | USE OF 5-FLUORO-2'-DEOXY-3'-THIACYTIDINE FOR THE TREATMENT OF HEPATITIS B | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285364-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | DHODH, DPYD, DLD | ALB 4480/4885POLG 1240/4885LMNA 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.